These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 30633263

  • 1. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z, Deng Z, Zhu G.
    Dalton Trans; 2019 Feb 19; 48(8):2536-2544. PubMed ID: 30633263
    [Abstract] [Full Text] [Related]

  • 2. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Gibson D.
    J Inorg Biochem; 2021 Apr 19; 217():111353. PubMed ID: 33477089
    [Abstract] [Full Text] [Related]

  • 3. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H, Wang X, Gou S.
    J Inorg Biochem; 2019 Apr 19; 193():133-142. PubMed ID: 30731264
    [Abstract] [Full Text] [Related]

  • 4. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis.
    Ma L, Ma R, Wang Z, Yiu SM, Zhu G.
    Chem Commun (Camb); 2016 Sep 14; 52(71):10735-8. PubMed ID: 27506281
    [Abstract] [Full Text] [Related]

  • 5. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z, Xu Z, Zhu G.
    Angew Chem Int Ed Engl; 2016 Dec 12; 55(50):15564-15568. PubMed ID: 27736029
    [Abstract] [Full Text] [Related]

  • 6. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
    Ai F, Sun T, Xu Z, Wang Z, Kong W, To MW, Wang F, Zhu G.
    Dalton Trans; 2016 Aug 16; 45(33):13052-60. PubMed ID: 27430044
    [Abstract] [Full Text] [Related]

  • 7. CAIXplatins: Highly Potent Platinum(IV) Prodrugs Selective Against Carbonic Anhydrase IX for the Treatment of Hypoxic Tumors.
    Cao Q, Zhou DJ, Pan ZY, Yang GG, Zhang H, Ji LN, Mao ZW.
    Angew Chem Int Ed Engl; 2020 Oct 12; 59(42):18556-18562. PubMed ID: 32557982
    [Abstract] [Full Text] [Related]

  • 8. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M, Hartinger CG.
    Future Med Chem; 2018 Mar 01; 10(6):615-617. PubMed ID: 29411994
    [Abstract] [Full Text] [Related]

  • 9. Copper-free click-chemistry platform to functionalize cisplatin prodrugs.
    Pathak RK, McNitt CD, Popik VV, Dhar S.
    Chemistry; 2014 Jun 02; 20(23):6861-5. PubMed ID: 24756923
    [Abstract] [Full Text] [Related]

  • 10. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
    Babu T, Sarkar A, Karmakar S, Schmidt C, Gibson D.
    Inorg Chem; 2020 Apr 06; 59(7):5182-5193. PubMed ID: 32207294
    [Abstract] [Full Text] [Related]

  • 11. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
    Qiao X, Gao YY, Zheng LX, Ding XJ, Xu LW, Hu JJ, Gao WZ, Xu JY.
    Eur J Med Chem; 2021 Nov 05; 223():113730. PubMed ID: 34388483
    [Abstract] [Full Text] [Related]

  • 12. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
    Deng Z, Zhu G.
    Curr Opin Chem Biol; 2023 Jun 05; 74():102303. PubMed ID: 37075513
    [Abstract] [Full Text] [Related]

  • 13. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C, Ding B, Zhang X, Deng X, Deng K, Cheng Z, Xing B, Jin D, Ma P, Lin J.
    Biomaterials; 2018 Feb 05; 155():112-123. PubMed ID: 29175080
    [Abstract] [Full Text] [Related]

  • 14. Imidazole modified Pt(iv) prodrug-loaded multi-stage pH responsive nanoparticles to overcome cisplatin resistance.
    Kang X, Wang Y, Chen Z, Wu Y, Chen H, Yang X, Yu C.
    Chem Commun (Camb); 2020 Sep 28; 56(76):11271-11274. PubMed ID: 32830841
    [Abstract] [Full Text] [Related]

  • 15. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 16. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
    Gabano E, Ravera M, Zanellato I, Tinello S, Gallina A, Rangone B, Gandin V, Marzano C, Bottone MG, Osella D.
    Dalton Trans; 2017 Oct 24; 46(41):14174-14185. PubMed ID: 28984330
    [Abstract] [Full Text] [Related]

  • 17. Corrosion-Activated Chemotherapeutic Function of Nanoparticulate Platinum as a Cisplatin Resistance-Overcoming Prodrug with Limited Autophagy Induction.
    Cheng HJ, Wu TH, Chien CT, Tu HW, Cha TS, Lin SY.
    Small; 2016 Nov 24; 12(44):6124-6133. PubMed ID: 27717137
    [Abstract] [Full Text] [Related]

  • 18. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L, Lin X, Li C, Xu Z, Chan CY, Tse MK, Shi P, Zhu G.
    Inorg Chem; 2018 Mar 05; 57(5):2917-2924. PubMed ID: 29436828
    [Abstract] [Full Text] [Related]

  • 19. Pt(IV) Prodrug Photoactivation: A Promising Strategy for Cancer Therapy.
    Tang L, Luo Y, Luo W, Sun G, Jiang Y, Zhang Z, Yue X, Li S, Liang L, Liu W, Hu J.
    Curr Protein Pept Sci; 2024 Mar 05; 25(10):797-813. PubMed ID: 38919078
    [Abstract] [Full Text] [Related]

  • 20. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D.
    Dalton Trans; 2016 Aug 16; 45(33):12983-91. PubMed ID: 27214873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.